|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2010-10-4
|
|
pubmed:abstractText |
Antibody drug conjugates (ADCs) combine the ideal properties of both antibodies and cytotoxic drugs by targeting potent drugs to the antigen-expressing tumor cells, thereby enhancing their antitumor activity. Successful ADC development for a given target antigen depends on optimization of antibody selection, linker stability, cytotoxic drug potency, and mode of linker-drug conjugation to the antibody. Here, we systematically examined the in vitro potency as well as in vivo preclinical efficacy and safety profiles of a heterogeneous preparation of conventional trastuzumab-mcc-DM1 (TMAb-mcc-DM1) ADC with that of a homogeneous engineered thio-trastuzumab-mpeo-DM1 (thioTMAb-mpeo-DM1) conjugate. Experimental Design and
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Maytansine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfhydryl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BhaktaSunilS,
pubmed-author:DuggerDebra LDL,
pubmed-author:FlagellaKelly MKM,
pubmed-author:FujiReina NRN,
pubmed-author:GrahamRichard ARA,
pubmed-author:HaEdwardE,
pubmed-author:HiraragiHajimeH,
pubmed-author:JunutulaJagath RJR,
pubmed-author:Lewis PhillipsGail DGD,
pubmed-author:LiGuangminG,
pubmed-author:MaiElaineE,
pubmed-author:NguyenTrungT,
pubmed-author:ParsonsKathryn LKL,
pubmed-author:PolakisPaulP,
pubmed-author:RaabHelgaH,
pubmed-author:SchellerRichard HRH,
pubmed-author:SliwkowskiMark XMX,
pubmed-author:SpencerSusan DSD,
pubmed-author:TibbittsJayJ,
pubmed-author:VandlenRichardR
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4769-78
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20805300-Animals,
pubmed-meshheading:20805300-Antibodies, Monoclonal,
pubmed-meshheading:20805300-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20805300-Antineoplastic Agents,
pubmed-meshheading:20805300-Breast Neoplasms,
pubmed-meshheading:20805300-Cell Line, Tumor,
pubmed-meshheading:20805300-Cell Proliferation,
pubmed-meshheading:20805300-Cell Survival,
pubmed-meshheading:20805300-Dose-Response Relationship, Drug,
pubmed-meshheading:20805300-Drug Design,
pubmed-meshheading:20805300-Drug Screening Assays, Antitumor,
pubmed-meshheading:20805300-Drug Toxicity,
pubmed-meshheading:20805300-Female,
pubmed-meshheading:20805300-Humans,
pubmed-meshheading:20805300-Macaca fascicularis,
pubmed-meshheading:20805300-Mammary Neoplasms, Experimental,
pubmed-meshheading:20805300-Maytansine,
pubmed-meshheading:20805300-Mice,
pubmed-meshheading:20805300-Rats,
pubmed-meshheading:20805300-Rats, Sprague-Dawley,
pubmed-meshheading:20805300-Receptor, erbB-2,
pubmed-meshheading:20805300-Sulfhydryl Compounds
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
|
|
pubmed:affiliation |
Genentech, Inc., South San Francisco, California 94080, USA. jagath@gene.com
|
|
pubmed:publicationType |
Journal Article
|
